Over the past decade, more than 1.2 million people have been treated with Celgene therapies as the company continues to deliver on its promise to improve the lives of patients worldwide.
Beyond a long-standing commitment to discovering, developing and commercializing new medicines for patients with unmet needs, this year Celgene published our long-standing pricing principles to increase transparency, made a public commitment to specific environmental goals for the year 2020, and increased our efforts on behalf of patients by working with approximately 150 patient groups around the world.
“Patients are at the center of everything we do at Celgene,” Mark J. Alles, CEO of Celgene, said. “Putting patients first is the purpose that binds us all together. It’s who we are.”
For the first time, Celgene received third-party feedback on its corporate responsibility efforts from 50 stakeholders across the health care ecosystem, including: global health, patient advocacy, environmental management, and public policy experts. The insights from these discussions will help inform the company’s future priorities in corporate responsibility and focus on those that provide both business and societal value.
Collaborative discussions revealed patient access to be a top priority for both Celgene and its stakeholders. Celgene collaborates with providers, payers, patient advocacy groups and governments to ensure access to its therapies and helps patients directly through the U.S.-based Celgene Patient Support® program.
“Access to health care remains a significant global challenge in both developed and developing countries,” said Joel Beetsch, Vice President for Patient Advocacy at Celgene. “Improving access to innovative therapies ensures that patients have every chance possible to live longer and more productive lives.”
Putting patients first is the purpose that binds us all together. It’s who we are.
Access and institutional capacity are also front and center in The Academic Model Providing Access to Healthcare (AMPATH) Consortium, one of Celgene’s global health partnerships. AMPATH’s Oncology Institute is one of the few international, multi-institutional collaborative cancer programs in sub-Saharan Africa. AMPATH Oncology addresses all phases of cancer care: prevention & screening; diagnosis & treatment; and palliative care & bereavement services. Celgene’s support to the AMPATH Oncology Institute has contributed to the provision of comprehensive clinical oncology services in 5 clinical sites. Celgene is providing robust assistance to AMPATH’s pharmacy infrastructure and novel patient care strategies — including education for patients with hematologic disorders, pharmaceutical supply chain enhancement, physical infrastructure support, and the development of a pharmacy residency training program.
Improving patients’ lives around the world is only made possible by the commitment of approximately 7,000 Celgene employees to fulfilling the company’s mission and creating a positive impact in their communities. In 2015, Celgene ranked 12th in Science Careers Top Employers Survey of the companies with the best reputations as employers and named the top biopharma partner for the Leukemia and Lymphoma Society’s “Light the Night” fundraising campaign.
That broader perspective of making a difference in the community led Celgene in December to pledge publicly to meet quantifiable prospective environmental targets. These goals for 2020 include reducing greenhouse gas emissions, increasing purchasing of renewable electricity and reducing water withdrawal and solid waste generation.
“Human health is clearly correlated to the health of the planet,” Zeba Khan, Vice President for Corporate Responsibility at Celgene, said. “These goals were intended to be ambitious yet realistic. As we continue to work to minimize our impact on the planet, these goals will help us to aim higher and do better.”
Those environmental goals stem from the company’s culture of integrity, which has led the company to share its perspective and experience in public policy discussions. For instance, Celgene strongly supports oral oncology parity laws that provide patients more affordable access to treatments, regardless of the form in which that treatment is made available.
These Celgene initiatives, and many others, align with not only the company’s corporate responsibility priorities but also Celgene’s purpose, which drives Celgene’s employees around the world — day in, day out.
To learn more about how Celgene is constantly striving to put patients first, read the 2016 Celgene Corporate Responsibility Report.